Method for treating ischemic tissue
AssigneeSt. Elizabeth's Medical Center of Boston, Inc.
InventorJeffrey M. Isner
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treating ischemic tissue in a mammal which comprises injecting said tissue with an effective amount of a nucleic acid capable of expressing an angiogenic protein. The method of the present invention may be used to treat any ischemic tissue, i.e., a tissue having a deficiency in blood as the result of an ischemic disease. Such tissues can include, for example, muscle, brain, kidney and lung. Ischemic diseases include, for example, cerebrovascular ischemia, renal ischemia, pulmonary ischemia, limb ischemia, ischemic cardiomyopathy and myocardial ischemia.
Claims30
A method for inducing the formation of new blood vessels in an ischemic muscle tissue in a human host, comprising:
- (a) selecting a human host in need of increased blood flow in an ischemic muscle tissue, and
- (b) directly injecting into said tissue of said human host an effective amount of a DNA sequence encoding an angiogenic protein or a modified angiogenic protein, wherein said DNA sequence comprises a promoter sequence and either a native secretory signal sequence or an operably linked secretory signal sequence, wherein the angiogenic protein or modified angiogenic protein is selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, endothelial cell growth factor, epidermal growth factor, transforming growth factor .alpha. and .beta., platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor, and insulin-like growth factor, and wherein said effective amount of said DNA sequence expresses sufficient angiogenic protein in said tissue to induce new blood vessel formation in said human host.
A method for inducing the formation of new blood vessels in ischemic limb muscle tissue in a human host, comprising:
- (a) selecting a human host in need of increased blood flow in ischemic limb muscle tissue, and
- (b) directly injecting into said tissue of said human host an effective amount of a DNA sequence encoding an angiogenic protein or a modified angiogenic protein, wherein said DNA sequence comprises a promoter sequence and either a native secretory signal sequence or an operably linked secretory signal sequence, said DNA sequence being free of an adenoviral vector, wherein the angiogenic protein or modified angiogenic protein is selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, endothelial cell growth factor, epidermal growth factor, transforming growth factor .alpha. and .beta., platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor, and insulin-like growth factor, and wherein said effective amount of said DNA sequence expresses sufficient angiogenic protein in said tissue to induce new blood vessel formation in said human host.
Dependencies are inferred from the claim text.